Regulus Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Regulus Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-96.1%
Buyback Yield
Total Shareholder Yield | -96.1% |
Future Dividend Yield | n/a |
Dividend Growth | n/a |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth
Sep 28Regulus surges 15% after Phase 1 data for kidney disease candidate
Sep 12Regulus Therapeutics GAAP loss per share narrows
Aug 11Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?
Oct 12The Read On Regulus Therapeutics
Aug 03We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now
Jun 09Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease
May 03Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)
Mar 13Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year
Mar 10Regulus Therapeutics announces closing of $19.4M private placement
Dec 08Regulus Therapeutics EPS beats by $0.17, beats on revenue
Nov 05Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if RGLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGLS's dividend payments have been increasing.
Dividend Yield vs Market
Regulus Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (RGLS) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.6% |
Industry Average (Biotechs) | 2.5% |
Analyst forecast (RGLS) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate RGLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate RGLS's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RGLS has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 11:30 |
End of Day Share Price | 2025/01/08 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Regulus Therapeutics Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
James Birchenough | BMO Capital Markets Equity Research |
James Birchenough | BMO Capital Markets U.S. (Historical) |
Madhu Kumar | B. Riley Securities, Inc. |